Last updated: September 4, 2026
Takeda’s ENTYVIO, or vedolizumab, is one of the largest inflammatory bowel disease biologics globally. Sales have grown from a launch-stage product into a roughly ¥800 billion annual franchise, supported by expansion in ulcerative colitis and Crohn’s disease, subcutaneous delivery, and durable physician adoption. The primary commercial risk is not an immediate U.S. generic event. It is the combination of U.S. biologic exclusivity expiration in 2026, later patent challenges, biosimilar development, and intensified competition from IL-23 and JAK therapies.
How much revenue does ENTYVIO generate?
ENTYVIO is Takeda’s leading growth product and one of its most important sources of recurring pharmaceutical revenue.
| Takeda fiscal year ending March 31 |
Approximate ENTYVIO revenue |
Commercial interpretation |
| FY2020 |
¥427 billion |
Expansion across major markets |
| FY2021 |
¥532 billion |
Continued uptake in ulcerative colitis and Crohn’s disease |
| FY2022 |
¥655 billion |
Broader gastroenterology use and international growth |
| FY2023 |
¥780 billion |
Franchise reached large-product scale |
| FY2024 |
Approximately ¥800 billion-plus |
Growth moderated but remained positive |
Takeda reports ENTYVIO sales in Japanese yen, so reported growth reflects both underlying demand and foreign-exchange movements. The product has remained one of the company’s largest revenue contributors despite increasing competition in inflammatory bowel disease [1, 2].
The franchise has several financial advantages:
- Chronic maintenance treatment creates recurring revenue.
- ENTYVIO is used in both ulcerative colitis and Crohn’s disease.
- Its gut-selective mechanism provides a differentiated safety and positioning profile.
- Subcutaneous delivery expands convenience and may retain patients who would otherwise switch.
- The product has substantial commercial infrastructure in gastroenterology.
The main limitation is market maturity. ENTYVIO is no longer gaining share from an underdeveloped treatment base. Future growth depends more on switching, earlier-line use, international penetration, and retention against newer mechanisms.
What is ENTYVIO approved to treat?
The FDA approved ENTYVIO in May 2014 for adults with moderately to severely active ulcerative colitis and Crohn’s disease who have had an inadequate response, loss of response, or intolerance to conventional therapy or a tumor necrosis factor blocker [3].
ENTYVIO dosage forms and delivery systems
The U.S. franchise includes:
| Product |
Strength |
Administration |
Commercial role |
| Intravenous ENTYVIO |
300 mg |
Infusion at weeks 0, 2, and 6, then generally every 8 weeks |
Initial and maintenance treatment |
| Subcutaneous ENTYVIO |
108 mg |
Injection every 2 weeks after induction |
Convenience, home administration, retention |
The FDA approved the subcutaneous formulation in 2023. The product is supplied as a prefilled syringe and, in applicable markets, an injection pen. Subcutaneous dosing gives Takeda a lifecycle-management tool as the original intravenous product approaches the end of regulatory exclusivity [4].
The subcutaneous formulation may protect revenue in three ways:
- It reduces dependence on infusion-center administration.
- It supports patient preference for home treatment.
- It creates a product-specific switching path before competing biosimilars become widely available.
The commercial value will depend on reimbursement, patient support, device usability, and whether payers treat the subcutaneous and intravenous products as interchangeable.
When does ENTYVIO lose regulatory exclusivity?
ENTYVIO received its original U.S. biologic license on May 20, 2014. Under the Biologics Price Competition and Innovation Act, a reference biologic generally receives 12 years of reference-product exclusivity. The core U.S. biologic exclusivity period therefore extends to May 20, 2026 [5].
This date does not automatically permit immediate biosimilar market entry. A biosimilar sponsor must complete the FDA approval process, satisfy the statutory patent-notice requirements, and resolve or manage any relevant patent litigation. The practical entry date could occur after May 2026.
ENTYVIO exclusivity timeline
| Event |
Date |
| FDA approval of intravenous ENTYVIO |
May 20, 2014 |
| Four-year biosimilar application data exclusivity |
May 20, 2018 |
| Twelve-year reference-product exclusivity |
May 20, 2026 |
| FDA approval of subcutaneous ENTYVIO in the U.S. |
2023 |
| First likely commercial pressure |
2026 onward |
| Higher erosion risk |
Late 2020s and early 2030s |
The 2026 date concerns regulatory exclusivity. Patent rights may extend beyond it, particularly for formulation, delivery, manufacturing, dosing, and subcutaneous-device claims.
What patents protect ENTYVIO?
ENTYVIO’s patent protection is layered rather than dependent on a single composition-of-matter patent. The relevant categories are:
- Antibodies binding the alpha-4-beta-7 integrin pathway.
- Humanized antibody sequences and related biologic constructs.
- Pharmaceutical compositions.
- Intravenous dosing regimens.
- Subcutaneous administration.
- Formulations and delivery devices.
- Manufacturing and purification processes.
The original antibody and platform patent families have earlier expiration dates than later lifecycle patents. As a result, the end of the basic antibody patent period does not necessarily remove every commercial barrier.
Are ENTYVIO patents listed in the Orange Book?
No. ENTYVIO is a biologic, not a small-molecule drug approved under a conventional FDA new drug application. Its patent information is assessed through the FDA Purple Book and the BPCIA patent-exchange process rather than the Orange Book listing system [5, 6].
The distinction matters:
- Orange Book patents apply primarily to drugs approved under the Federal Food, Drug, and Cosmetic Act.
- Purple Book records identify licensed biological products and biosimilar or interchangeable status.
- Patent disputes involving biosimilars proceed under the BPCIA framework and ordinary federal patent litigation.
- A biosimilar applicant does not use a conventional Abbreviated New Drug Application Paragraph IV certification.
Are there Paragraph IV challenges to ENTYVIO?
The conventional Paragraph IV pathway does not apply to ENTYVIO because it is a biologic. A biosimilar sponsor instead uses the BPCIA process and may provide a notice of commercial marketing, participate in patent information exchange, and litigate asserted patents.
As of the latest broadly available FDA product records, no vedolizumab biosimilar had received FDA approval. The absence of an approved biosimilar reduces immediate U.S. erosion risk, but it does not remove pipeline risk. Sponsors can file biosimilar applications before reference-product exclusivity expires, subject to the statutory timing rules.
What companies are challenging ENTYVIO?
Vedolizumab biosimilar development has attracted major biologics manufacturers and regional producers, including companies with late-stage or disclosed development programs. Publicly identified development activity has included Celltrion and other international biosimilar developers. The commercial threat is more credible when a candidate has completed comparative clinical development and entered regulatory review.
The competitive assessment should distinguish between:
- Preclinical candidates.
- Phase 1 pharmacokinetic and safety programs.
- Phase 3 comparative efficacy programs.
- Regulatory filings.
- Approved products with confirmed launch dates.
A development announcement alone does not establish a U.S. launch timetable.
How strong is the ENTYVIO patent estate?
ENTYVIO has a moderately strong near-term patent position and a less certain long-term position.
Strengths
- The product is a complex monoclonal antibody.
- Manufacturing comparability is difficult for biosimilar developers.
- Clinical use spans two large indications.
- Subcutaneous delivery creates additional formulation and device barriers.
- Takeda can litigate multiple patent families rather than relying on one claim set.
- Physician and payer switching may be slower than in conventional generic markets.
Weaknesses
- The primary U.S. biologic exclusivity period ends in 2026.
- The active ingredient is clinically established, reducing development risk for biosimilar competitors.
- Large commercial opportunity justifies investment by global biosimilar companies.
- Biosimilars do not need to reproduce every commercial attribute of the reference product.
- Payers may pressure providers to move patients to lower-cost alternatives once a credible biosimilar is available.
The most valuable remaining protection is likely to involve later-generation subcutaneous formulations, administration regimens, device configurations, and manufacturing claims. These patents can delay entry or limit the exact product configuration available to a biosimilar company, but they may not block every legally permissible alternative.
What competitive drugs are pressuring ENTYVIO?
ENTYVIO competes in a rapidly expanding inflammatory bowel disease market.
| Competitor |
Mechanism |
Commercial position |
| STELARA, ustekinumab |
IL-12/23 inhibitor |
Large established biologic with biosimilar pressure beginning in the U.S. |
| SKYRIZI, risankizumab |
IL-23 inhibitor |
High-growth competitor in Crohn’s disease and ulcerative colitis |
| RINVOQ, upadacitinib |
JAK inhibitor |
Oral option with strong efficacy but class safety restrictions |
| HUMIRA, adalimumab |
TNF inhibitor |
Mature product with extensive biosimilar competition |
| REMICADE, infliximab |
TNF inhibitor |
Infusion-based competitor with biosimilar erosion |
| OMVOH, mirikizumab |
IL-23 inhibitor |
Newer ulcerative colitis competitor |
| TREMFYA, guselkumab |
IL-23 inhibitor |
Expanding into inflammatory bowel disease |
ENTYVIO’s main strategic advantage is selectivity for the gut through alpha-4-beta-7 integrin blockade. Its principal competitive disadvantage is slower onset or lower efficacy perception in some treatment settings compared with high-efficacy IL-23 and JAK therapies.
How does ENTYVIO compare with SKYRIZI and RINVOQ?
| Attribute |
ENTYVIO |
SKYRIZI |
RINVOQ |
| Modality |
Monoclonal antibody |
Monoclonal antibody |
Oral small molecule |
| Main mechanism |
Alpha-4-beta-7 integrin blockade |
IL-23 inhibition |
JAK1 inhibition |
| Administration |
IV or subcutaneous |
IV induction and subcutaneous maintenance, depending on indication |
Oral |
| Key positioning |
Gut-selective safety profile |
High-efficacy biologic |
Convenience and rapid activity |
| Patent risk |
Biosimilar risk after 2026; later formulation patents |
Longer remaining commercial runway |
Small-molecule patent and safety exposure |
| Principal risk |
Loss of share to newer mechanisms and biosimilars |
Future class competition |
Regulatory warnings and boxed-warning concerns |
ENTYVIO is better positioned when physicians prioritize gut selectivity and long-term safety. SKYRIZI and RINVOQ are stronger threats in patients requiring rapid or high-intensity disease control.
What is the FDA regulatory status of ENTYVIO?
ENTYVIO is FDA-approved for adult ulcerative colitis and Crohn’s disease. The intravenous and subcutaneous products are approved for maintenance treatment under their respective dosing instructions [3, 4].
No interchangeable vedolizumab biosimilar had been approved in the FDA Purple Book as of the latest available product records. Interchangeability would be commercially meaningful because pharmacy-level substitution rules generally apply more directly to an interchangeable biosimilar than to a noninterchangeable biosimilar [6].
The absence of an approved biosimilar supports continued near-term pricing power, although payer pressure can begin before formal interchangeability.
What generic or biosimilar launch scenarios exist for ENTYVIO?
Scenario 1: Delayed biosimilar entry
A biosimilar reaches approval after May 2026 but launches only after patent litigation or a negotiated settlement. This would extend Takeda’s effective exclusivity and protect revenue in the late 2020s.
Scenario 2: Single early entrant
One biosimilar launches with limited payer coverage. ENTYVIO retains a substantial share through contracting, physician familiarity, patient-support services, and subcutaneous conversion.
Scenario 3: Multiple biosimilar entrants
Several products launch within a compressed period. Net pricing declines faster, and infusion-center economics favor lower-cost products. Takeda’s subcutaneous product may slow erosion but may not preserve historical price levels.
Scenario 4: Formulation-led defense
Takeda shifts patients from intravenous ENTYVIO to the subcutaneous product before biosimilar launches. The strategy protects treatment continuity but can be challenged if biosimilar sponsors develop comparable subcutaneous presentations or if payers mandate switching.
The most probable commercial pattern is gradual erosion rather than an immediate small-molecule-style collapse. Biologic market share changes depend on payer contracting, provider administration economics, interchangeability, and manufacturing supply.
What patent litigation and settlement risks affect ENTYVIO?
Potential litigation would likely focus on:
- Antibody and sequence claims.
- Dosing regimens.
- Subcutaneous formulations.
- Device and container claims.
- Stability and manufacturing processes.
A settlement could establish a licensed biosimilar entry date before the last asserted patent expires. Such agreements are common tools for controlling launch timing, but their terms may remain confidential or be disclosed only in regulatory filings.
The absence of a public, definitive U.S. launch settlement does not eliminate litigation risk. It indicates that the commercial timetable remains dependent on future filings, patent assertions, and biosimilar regulatory progress.
What licensing deals support ENTYVIO?
ENTYVIO originated from antibody technology associated with Millennium Pharmaceuticals, which Takeda acquired in 2008. Takeda has controlled global commercialization and development of the product.
The main strategic asset is therefore internal ownership and lifecycle control rather than a widely disclosed external commercialization license. Any royalty or technology obligations connected to antibody-platform rights can affect product margins, but Takeda’s financial disclosures do not present ENTYVIO as a heavily partnered product comparable to a co-commercialized asset [1].
How much revenue is exposed to ENTYVIO patent loss?
At approximately ¥800 billion or more in annual sales, ENTYVIO represents a material share of Takeda’s pharmaceutical revenue. A 10% decline in global net sales would imply roughly ¥80 billion in annual revenue exposure before offsets from price, volume, geographic mix, and foreign-exchange movements.
| Erosion level |
Approximate annual revenue impact |
| 10% decline |
¥80 billion |
| 20% decline |
¥160 billion |
| 30% decline |
¥240 billion |
| 50% decline |
¥400 billion |
These figures are directional calculations based on a ¥800 billion annual sales base. The impact on operating profit would vary because manufacturing costs, selling expenses, royalties, and patient-support costs would not decline proportionally.
ENTYVIO’s importance to Takeda makes the franchise a central component of the company’s post-2026 revenue planning. Growth from newer assets, including gastrointestinal and oncology products, will determine whether ENTYVIO erosion creates a material portfolio gap.
What is the long-term market outlook for ENTYVIO?
ENTYVIO is likely to remain a major IBD product after 2026, but its growth profile should change.
The base case is:
- Continued revenue growth or stability before biosimilar approval.
- Increasing subcutaneous penetration.
- Greater payer scrutiny after reference-product exclusivity ends.
- Gradual price and volume erosion once one or more biosimilars launch.
- Share pressure from IL-23 therapies in treatment-naive and biologic-experienced patients.
- Continued use in patients prioritizing gut-selective therapy and established safety experience.
The franchise has stronger durability than a mature small-molecule product because biologic substitution is slower and manufacturing barriers are higher. It has weaker long-term protection than an asset with a new chemical entity patent extending well beyond regulatory exclusivity.
Key Takeaways
- ENTYVIO is Takeda’s largest or one of its largest revenue products, with annual sales around ¥800 billion.
- FDA approval occurred on May 20, 2014, placing the 12-year U.S. biologic exclusivity date at May 20, 2026.
- ENTYVIO is not an Orange Book drug. Biosimilar competition proceeds through the Purple Book and BPCIA framework.
- No approved U.S. vedolizumab biosimilar had been listed in the latest available FDA records.
- The subcutaneous formulation is Takeda’s primary lifecycle-management defense.
- Patent protection extends beyond core biologic exclusivity through formulation, dosing, device, and manufacturing claims, although the strength of those barriers depends on claim scope and litigation outcomes.
- SKYRIZI, RINVOQ, OMVOH, TREMFYA, STELARA, and TNF inhibitors create sustained competitive pressure.
- A 20% decline from an ¥800 billion sales base would represent approximately ¥160 billion in annual revenue exposure.
- The likely erosion pattern is gradual, with timing determined by biosimilar approvals, patent settlements, payer policy, and subcutaneous conversion.
FAQs
Is ENTYVIO a biologic or a generic drug?
ENTYVIO is a biologic monoclonal antibody. Its active ingredient is vedolizumab, and competing products would be biosimilars rather than conventional generics.
Does ENTYVIO have an interchangeable biosimilar?
No interchangeable vedolizumab biosimilar had been listed in the latest available FDA Purple Book records.
Can patients switch directly from intravenous ENTYVIO to subcutaneous ENTYVIO?
The FDA label provides dosing instructions for transitioning eligible patients from intravenous induction to subcutaneous maintenance. The switch must follow the approved prescribing information and clinical judgment.
Will ENTYVIO sales fall immediately in 2026?
Not necessarily. May 2026 ends the principal U.S. biologic exclusivity period, but commercial entry depends on biosimilar approval, patent litigation, settlements, payer adoption, and supply capacity.
Which ENTYVIO patent category has the greatest commercial importance?
Later formulation, subcutaneous delivery, device, dosing, and manufacturing patents are likely to have greater commercial importance than expired or expiring foundational antibody patents because they can affect the timing and configuration of biosimilar launches.
References
- Takeda Pharmaceutical Company Limited. (2024). Annual report 2024.
- Takeda Pharmaceutical Company Limited. (2025). Fiscal year 2024 consolidated financial results.
- U.S. Food and Drug Administration. (2024). ENTYVIO prescribing information.
- U.S. Food and Drug Administration. (2023). FDA approves subcutaneous formulation of ENTYVIO for ulcerative colitis and Crohn’s disease.
- U.S. Congress. (2010). Patient Protection and Affordable Care Act, Biologics Price Competition and Innovation Act provisions.
- U.S. Food and Drug Administration. (2025). Purple Book: Database of licensed biological products.
